Last updated: March 13, 2026
What is NDC 16571-0697?
NDC 16571-0697 corresponds to Duarte's Vonoprazan Fumarate tablets. Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for gastroesophageal reflux disease (GERD) and erosive esophagitis. It is approved in Japan and some other markets but not yet widely available in the U.S.
Market Overview
Market Size
- Global GERD Treatment Market: Valued at approximately USD 10 billion in 2022.
- Japan's GERD Market: Estimated at USD 800 million, with increasing adoption of P-CABs.
- Potential U.S. Entry: The U.S. market exceeds USD 5 billion for proton pump inhibitors (PPIs) and alternatives for GERD.
Competitive Landscape
- Key Competitors:
- Proton pump inhibitors (PPIs): Esomeprazole, Omeprazole, Lansoprazole.
- Other P-CABs: Takeda's Vonoprazan (market leader in Japan).
- Emerging drugs with novel mechanisms or improved safety profiles.
Regulatory Status
- Japan: Approved since 2015; robust sales growth.
- U.S.: Pending FDA approval; data from clinical trials submitted.
- Other Markets: Approved or in phase 3 development in Europe, South Korea.
Pricing and Cost Dynamics
Current Pricing (Japan)
- Brand-Name Vonoprazan: Approximately JPY 600–800 per tablet (~USD 5–7).
- Generic PPI equivalents: USD 1–3 per tablet.
Expected Price Trajectory in Key Markets
| Market |
2023 Price Estimate (per unit) |
2028 Price Projection |
Notes |
| Japan |
USD 5–7 |
USD 5–7 |
Stable, premium brand; no generics yet |
| U.S. |
USD 8–12 (initial launch) |
USD 6–8 |
Premium pricing due to novelty, cost-effective generics possible in future |
| Europe |
USD 7–9 |
USD 6–8 |
Similar to Japan, regulatory and reimbursement negotiations ongoing |
Pricing Drivers
- Market Penetration: Competition from established PPIs below USD 3 per tablet impacts initial pricing.
- Regulatory Approvals: U.S. approval expected to influence pricing strategies.
- Reimbursement Policies: Countries with government-insured healthcare programs favor lower prices.
Revenue Projections
Assumptions
- Launch Year: 2023 in Japan; 2024 in U.S.
- Market Capture:
- Japan: 30% share of GERD market within 3 years.
- U.S.: 15% share within 5 years, assuming FDA approval.
- Pricing:
- Japan: USD 6 per tablet.
- U.S.: USD 10 per tablet initially, reducing to USD 7 over 5 years as generics enter.
Sales Volume Estimates (First 5 Years)
| Year |
Japan Units (million) |
U.S. Units (million) |
Japan Revenue (USD millions) |
U.S. Revenue (USD millions) |
| 2023 |
2 |
0 |
36 |
0 |
| 2024 |
4 |
2 |
72 |
40 |
| 2025 |
6 |
4 |
108 |
80 |
| 2026 |
8 |
6 |
144 |
84 |
| 2027 |
10 |
8 |
180 |
84 |
Note: These are simplified estimates based on market share assumptions, known pricing, and treatment durations.
Sensitivity Considerations
- Market Penetration: Slower uptake limits sales; aggressive marketing and clinical advantages drive faster growth.
- Pricing Adjustments: Introduction of generics could reduce prices by 20%–30%, impacting revenue.
- Regulatory Delays: FDA approval timing influences the launch and revenue realization.
Key Takeaways
- The drug's market depends heavily on successful entry into the U.S. market.
- Prices are expected to decline as generics and biosimilars gain approval.
- Japan remains a stable revenue source due to existing approval and market presence.
- Competitors' pipelines and regulatory hurdles present both risks and opportunities.
- Achieving market share targets requires clinician education and reimbursement negotiations.
FAQs
1. When is FDA approval for NDC 16571-0697 expected?
Expected approval is likely in 2024, contingent on completing ongoing clinical trials and submitting sufficient data.
2. What factors could influence the drug’s price in the U.S.?
Regulatory approval, competition from generics, reimbursement negotiations, and formulary placements.
3. How does the drug compare to existing PPIs in terms of cost?
Initially priced higher (USD 8–12 per tablet) versus PPIs (~USD 1–3), with potential for price reductions post-generic entry.
4. What is the potential size of the U.S. market for this drug?
Estimated at USD 1–2 billion annually once fully launched and captured market share.
5. What regulatory hurdles exist for expanding into Europe?
The European Medicines Agency (EMA) requires comprehensive clinical data and local approval processes, similar to FDA stages.
References
[1] MarketWatch. (2023). GERD Treatment Market Size & Trends.
[2] IQVIA. (2022). Global Biosimilars & Generics Report.
[3] Japan Pharmaceuticals & Medical Devices Agency. (2022). Vonoprazan approval status.
[4] FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
[5] Transparency Market Research. (2023). Acid Suppressants Market Analysis.
